Hi Nutri ,
I think noone seriously doubts that attacking the Bcl-2 Protein ( the covershield of the cancer cell against chemo ) is a promising path . It is also nice to see Genta named among the " big players " - but thats not enough as you and me and all other investors know. In simple words : We know that it works , but we dont know how to make it work in a bigger number of patients ( regarding PPS and OS ) . LDH range in patients is nothing else than a parameter for each patient to understand how worst his / hers situation is in comparison to future perspective on a successful medicamentation. Those with a high LDH ratio are still uncureable. Sad but true. Ray himself told this in a videoclip shortly before the leak came out ( I think it has been 2-3 weeks earlier prior to the leak ). So my take on that videoclip is that it is a fact that Genasense works .But the OS is the very last hope for the Agenda trial. Remember , april the 15th 2009 , the last patient in Agenda was enrolled, 168 days after 8 cycles this patient - and therefor Agenda dates could be counted down to be published . So even with the last patients trial infos we are now ( since September - 15th april + 168 days ) 8 month after the last patient regarding OS. The other 314 patients provided Agenda with even more mature dates. To make the long story short : IF ! 300 patients of Agenda finished their trial at march 2009 , the test results of these patients are older than 12 month AND Agenda would be automatically unblinded if 50% of Agenda patients would have past away.( that is my understanding from the Agenda / IMB management )
So , pretty soon there should be / could be some news .
Cheers, BG
